RALEIGH, N.C., Feb. 23, 2017 /PRNewswire/ — BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced today that it has entered into a senior credit facility with affiliates of CRG LP, a ...
Anyone who’s ever endured a migraine knows all too well the experience of waiting for the meds to kick in and hoping the nausea isn’t so bad they are vomited up before that happens. BioDelivery ...
BioDelivery Sciences International (NASDAQ:BDSI) is running low on cash and running short on time as it works to find a drug partner before it runs out of both. The company has $15.1 million in cash — ...
A pain drug candidate from BioDelivery Sciences International (NASDAQ:BDSI) failed to perform better than a placebo in phase 3 clinical trials, according to preliminary trial results released by the ...
RALEIGH, N.C., May 28, 2015 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) has strengthened its sales and managed markets teams to support the launch of BUNAVAIL® ...
RALEIGH, N.C., Dec. 16, 2015 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced a number of changes to it senior management staff. BDSI has promoted Dr. Niraj Vasisht to ...
MORRISVILLE, N.C.--(BUSINESS WIRE)--BioDelivery Sciences International, Inc. (Nasdaq: BDSI, http://www.biodeliverysciences.com) has submitted its New Drug Application ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Raleigh’s BioDelivery Sciences International has closed ...
RALEIGH - BioDelivery Services International is taking the precaution of developing a safety plan for its patch designed for cancer patients who suffer "breakthrough pain." Al Medwar, vice president ...
MonoSol Rx announced that the U.S. Patent and Trademark Office (USPTO) will decide by August 2015 whether BioDelivery Sciences International's ($BDSI) BEMA drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results